Kinase News and Research

RSS

Researchers identify potential targets for more effective analgesic drugs with potentially fewer side effects

Studying mice, pain researchers at Washington University School of Medicine in St. Louis have identified two key components in the pain cascade that may provide targets for more effective analgesic drugs with potentially fewer side effects

6 Apr 2006

Divergent behavioral roles of angiotensin receptor intracellular signaling cascades

Researchers at the University at Buffalo and the University of Pennsylvania were the first to demonstrate that two intracellular events, both stimulated by the same cell receptor, can provoke different behaviors in mammals.

23 Mar 2006

Therapy for metastatic renal cell carcinoma remains inadequate

The recent FDA approvals of the tyrosine kinase inhibitors sorafenib and sunitinib based on their activity in metastatic renal cell carcinoma have excited the medical oncology community

9 Mar 2006

Lilly launches phase III trial of Enzastaurin

One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today.

9 Mar 2006

New way to study proteins in live cells

For the first time, Johns Hopkins researchers were able to easily jumpstart the activity of a well-known cancer protein in live cells with a small molecule, a strategy that pinpointed key players in the cancer process and can be used to determine new therapeutic targets.

9 Mar 2006

Metabolic switch required for cellular adaptation to hypoxia

Two new studies in the March Cell Metabolism reveal a survival mechanism by which cells adapt to oxygen starvation by ratcheting down their demand.

9 Mar 2006

New mechanism that regulates K-Ras - protein that plays an important role in cancer

Researchers have discovered a protein widely known to cause the out-of-control growth of cells can actually be manipulated to induce those cells to commit suicide, providing a novel target for the development of anti-cancer drugs, according to the results of a new study led by New York University School of Medicine researchers.

21 Feb 2006

Genzyme launches test to monitor Gleevec resistance

Genzyme Corporation has announced the availability of an important new test to monitor drug resistance in chronic myeloid leukemia (CML) patients who are treated with Gleevec (imatinib mesylate).

13 Feb 2006

Statins show beneficial effect on rheumatoid arthritis

Statins, a class of drugs widely used to treat high cholesterol, have also recently been studied for their potential role in inflammation and other cell processes, including immune response.

13 Feb 2006

Chink in cancer's armor

Much as the famed starship Enterprise would deploy a deflector shield to evade enemy attack, tumor cells are capable of switching on a molecular force field of their own to fend off treatments aimed at killing them. Now University of Florida researchers have found a chink in their armor.

13 Feb 2006

Monotherapy phase I clinical trials of novel cytotoxics, targeted therapeutics, antimetastatic agents/angiogenesis inhibitors, and immunotherapeutics/vaccines

Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR)

7 Feb 2006

Fatty acids such as those found in corn oil turn on genes that stimulate tumor growth

Omega-6 fatty acids--such as those found in corn oil--caused human prostate tumors in cell culture to grow twice as quickly as tumors to which omega-6 fats had not been added, according to a study conducted at the San Francisco VA Medical Center.

5 Feb 2006

Bidirectional behavioral plasticity of memory reconsolidation depends on amygdalar protein kinase A

When activated, a specific protein in the brain enhances long-term storage of fearful memories and strengthens previously established fearful memories, Yale School of Medicine researchers report this week in Nature Neuroscience.

23 Jan 2006

Mutated oncogene triggers aggressive breast cancer

Researchers at Dana-Farber Cancer Institute have identified a molecular interaction that triggers a particularly aggressive form of breast cancer, and suggest that attacking this target with selective drugs might improve treatment.

18 Jan 2006

Protein finding could lead to new topical treatment for inflammatory diseases

A protein that undesirably shields a skin poxvirus from the immune system may become the key ingredient in a new topical treatment for inflammatory diseases, say medical researchers at the University of Illinois at Urbana-Champaign.

11 Jan 2006

Researchers move closer to understanding the basis of a severe epilepsy and mental retardation

Researchers at the University of California, San Diego (UCSD) School of Medicine took a step closer to understanding the basis of a severe epilepsy and mental retardation syndrome with work published in the January 5, 2006 issue of the journal Neuron.

5 Jan 2006

Imatinib mesylate (Gleevec) may not be effective at treating kidney cancer

Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs), is not likely to be effective for patients with high grade renal cell carcinoma -- the most aggressive kidney cancer.

22 Dec 2005

AMN107 drug shows promise in leukemia resistance to Gleevec

The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.

13 Dec 2005

Ack1 molecule stimulates the aggressive growth of prostate cancer

The molecule, Ack1, a member of the growth-promoting tyrosine kinase gene family, stimulates tumor formation in part by signaling prostate cells to rid themselves of a tumor-suppressor protein. Normally, this suppressor protein would inhibit rapid cell growth by signaling the cell to destroy itself.

5 Dec 2005

Findings may help in development of new anti-inflammatory compounds

Virginia Commonwealth University researchers studying the enzyme that triggers inflammation have found that it may be a target for a new class of anti-inflammatory drugs to treat arthritis, asthma, multiple sclerosis, lung and colon cancers and Alzheimer's disease.

2 Dec 2005